[{"abstract": "The deal creating a pharmaceutical giant is the first big merger backed by Wall Street in months.", "web_url": "https://www.nytimes.com/2009/01/26/business/26drug.html", "snippet": "The deal creating a pharmaceutical giant is the first big merger backed by Wall Street in months.", "lead_paragraph": "The board of Pfizer, the world\u2019s largest drug maker, agreed to acquire a rival, Wyeth, for $68 billion, the companies announced Monday. ", "print_section": "A", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2009/01/26/business/27pfizer600.jpg", "height": 362, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2009/01/26/business/27pfizer600.jpg", "xlargewidth": 600, "xlargeheight": 362}}], "headline": {"main": "Pfizer Agrees to Pay $68 Billion for Rival Drug Maker Wyeth", "kicker": null, "content_kicker": null, "print_headline": "In Tight Market, Pfizer Agrees to Pay $68 Billion for Rival Wyeth", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Wyeth", "rank": 3, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 4, "major": "N"}], "pub_date": "2009-01-26T02:10:39+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Ross Sorkin and Duff Wilson", "person": [{"firstname": "Andrew", "middlename": "Ross", "lastname": "Sorkin", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Duff", "middlename": null, "lastname": "Wilson", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/57da4773-4e6d-572a-88c4-9fe149316688", "word_count": 1565, "uri": "nyt://article/57da4773-4e6d-572a-88c4-9fe149316688"}, {"abstract": "Pfizer will acquire Wyeth in a cash and stock deal valued at $68 billion, the companies said in a statement Monday morning.", "web_url": "https://dealbook.nytimes.com/2009/01/26/pfizer-to-buy-wyeth-in-68-billion-deal/", "snippet": "Pfizer will acquire Wyeth in a cash and stock deal valued at $68 billion, the companies said in a statement Monday morning.", "lead_paragraph": "Pfizer will acquire Wyeth in a cash and stock deal valued at $68 billion, the companies said in a statement Monday morning. ", "source": "The New York Times", "multimedia": [], "headline": {"main": "Pfizer to Buy Wyeth in $68 Billion Deal", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2009-01-26T12:14:04+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/188b884c-ccc1-549e-a546-e38bb34166e3", "word_count": 1021, "uri": "nyt://article/188b884c-ccc1-549e-a546-e38bb34166e3"}, {"abstract": "Matthew Nugen, who became national political director for Barack Obama\u2019s presidential campaign in early 2007, has started a new job as a strategic adviser for  Ogilvy Government Relations, a powerful lobbying firm whose clients include corporate giants such as Pfizer and big financial firms such as Blackstone.", "web_url": "https://dealbook.nytimes.com/2009/01/26/obama-aide-joins-ogilvy-as-adviser/", "snippet": "Matthew Nugen, who became national political director for Barack Obama\u2019s presidential campaign in early 2007, has started a new job as a strategic adviser for  Ogilvy Government Relations, a powerful lobbying firm whose clients include corporate g...", "lead_paragraph": "Matthew Nugen signed on as national political director for Barack Obama\u2019s presidential campaign in early 2007, giving him an important role in what even some of Mr. Obama\u2019s rivals have described as a remarkably well-run presidential bid. ", "source": "The New York Times", "multimedia": [], "headline": {"main": "Obama Aide Joins Ogilvy as Adviser", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2009-01-26T13:15:40+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/438b4a2a-63a1-5ef7-ba4a-20db6cee856a", "word_count": 504, "uri": "nyt://article/438b4a2a-63a1-5ef7-ba4a-20db6cee856a"}, {"abstract": "The price tag isn\u2019t the only big thing about Pfizer\u2018s deal to buy rival drug maker Wyeth. Pfizer is also aiming for big synergies from the $68 billion acquisition.", "web_url": "https://dealbook.nytimes.com/2009/01/26/pfizer-deal-calls-for-ambitious-cost-cuts/", "snippet": "The price tag isn\u2019t the only big thing about Pfizer\u2018s deal to buy rival drug maker Wyeth. Pfizer is also aiming for big synergies from the $68 billion acquisition.", "lead_paragraph": "The price tag isn\u2019t the only big thing about Pfizer\u2018s deal to buy the rival drug maker Wyeth. Pfizer is also aiming for big synergies from the $68 billion acquisition, announced Monday morning after days of speculation in the news media. That implies some serious cost cuts are in order.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Pfizer Deal Calls for Ambitious Cost Cuts", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2009-01-26T16:11:12+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By", "person": [], "organization": null}, "type_of_material": "News", "_id": "nyt://article/e0a2dc34-2e07-5e02-ba83-e5fa413c3c46", "word_count": 474, "uri": "nyt://article/e0a2dc34-2e07-5e02-ba83-e5fa413c3c46"}, {"abstract": "Monday\u2019s toll included 20,000 cuts at Caterpillar, 8,000 at Sprint Nextel, 7,000 at Home Depot and 8,000 from the expected merger of Pfizer and Wyeth.", "web_url": "https://www.nytimes.com/2009/01/27/business/economy/27jobcuts.html", "snippet": "Monday\u2019s toll included 20,000 cuts at Caterpillar, 8,000 at Sprint Nextel, 7,000 at Home Depot and 8,000 from the expected merger of Pfizer and Wyeth.", "lead_paragraph": "Employers have tried to nip and tuck their labor costs by reducing overtime, shortening the workweek and freezing wages, but now, they are reaching for the saw.", "source": "The New York Times", "multimedia": [], "headline": {"main": "62,000 Jobs Are Cut by U.S. and Foreign Companies", "kicker": null, "content_kicker": null, "print_headline": "A Day of Layoffs, Across Industries and Continents", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Sprint Nextel Corporation", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 2, "major": "N"}, {"name": "subject", "value": "Layoffs and Job Reductions", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Sprint Nextel Corp", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Home Depot Inc", "rank": 5, "major": "N"}, {"name": "subject", "value": "Subprime Mortgage Crisis", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Wyeth", "rank": 7, "major": "N"}], "pub_date": "2009-01-26T16:36:58+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "Economy", "byline": {"original": "By Jack Healy", "person": [{"firstname": "Jack", "middlename": null, "lastname": "Healy", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/6eed67f5-70cb-526c-b179-d4d28f51ede7", "word_count": 1071, "uri": "nyt://article/6eed67f5-70cb-526c-b179-d4d28f51ede7"}, {"abstract": "Pfizer\u2018s $68 billion deal to buy the rival drug maker Wyeth ranks among the largest pharmaceutical deals of all time. The acquisition, which is being paid for in cash and Pfizer stock, also breaks a long-running drought in the merger world, which hasn\u2019t seen such a large transaction (excluding spinoffs) since a group of banks bid nearly $96 billion for ABN Amro in April 2007.", "web_url": "https://dealbook.nytimes.com/2009/01/26/pfizers-prescription-for-growth-big-deals/", "snippet": "", "lead_paragraph": "Pfizer\u2018s $68 billion deal to buy the rival drug maker Wyeth ranks among the largest pharmaceutical deals of all time. The acquisition, which is being paid for in cash and Pfizer stock, also breaks a long-running drought in the merger world, which hasn\u2019t seen such a large transaction (excluding spinoffs) since a group of banks bid nearly $96 billion for ABN Amro in April 2007.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Pfizer\u2019s Prescription for Growth: Big Deals", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2009-01-26T17:27:45+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/2e7b3cec-323d-5a31-a9f7-ca9555ebfcd5", "word_count": 287, "uri": "nyt://article/2e7b3cec-323d-5a31-a9f7-ca9555ebfcd5"}, {"abstract": "Pfizer\u2019s planned acquisition of Wyeth is a validation of Wyeth\u2019s decision to reduce its reliance on small-molecule drugs.", "web_url": "https://www.nytimes.com/2009/01/27/business/27wyeth.html", "snippet": "Pfizer\u2019s planned acquisition of Wyeth is a validation of Wyeth\u2019s decision to reduce its reliance on small-molecule drugs.", "lead_paragraph": "Molecules.", "print_section": "B", "print_page": "4", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2009/01/27/business/27pfizer.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2009/01/27/business/27pfizer.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}], "headline": {"main": "In Wyeth, Pfizer Sees a Drug Pipeline", "kicker": null, "content_kicker": null, "print_headline": "In Pursuit of a Pipeline of Biological Treatments", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Biotechnology", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Wyeth", "rank": 5, "major": "N"}], "pub_date": "2009-01-26T19:21:15+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Natasha Singer", "person": [{"firstname": "Natasha", "middlename": null, "lastname": "Singer", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/62c902a8-ddbe-56fe-9f2e-11f63f134818", "word_count": 1104, "uri": "nyt://article/62c902a8-ddbe-56fe-9f2e-11f63f134818"}]